The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Ophthalmology (Rochester, Minn.)

• Publication date

  1998-10-01

• Fields of study

  Medicine

• Identifiers
  PMID 9787367
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dorzolamide versus pilocarpine as adjunctive therapies to timolol: a comparison of patient preference and impact on daily life.

  1996cited by this paper
• A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response Study Group.

  1996cited by this paper
• A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.

  1995cited by this paper
• Effectiveness and Tolerance of beta-Blocker/Pilocarpine Combination Eye Drops in Primary Open-Angle Glaucoma and High Intraocular Pressure.

  1995cited by this paper
• Regional variation in nephrolithiasis incidence and prevalence among United States men.

  1994cited by this paper
• Clinical experience with a fixed dose combination therapy of timolol and pilocarpine used twice daily in the management of chronic open angle glaucoma

  1994cited by this paper
• Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor.

  1993cited by this paper
• How often is medication taken as prescribed? A novel assessment technique.

  1989cited by this paper
• Timolol-pilocarpine combined vs timolol and pilocarpine given separately.

  1989cited by this paper
• Compliance with topical timolol treatment.

  1987cited by this paper
• Compliance with topical pilocarpine treatment.

  1986cited by this paper
• Compliance with treatment of patients with chronic open-angle glaucoma.

  1983cited by this paper
• Facilitating patient compliance in glaucoma therapy.

  1983cited by this paper
• Glaucoma patients not compliant with their drug therapy: clinical and behavioural aspects.

  1982cited by this paper
• Self-medication with pilocarpine among outpatients in a glaucoma clinic.

  1980cited by this paper

• Objective Evaluation of Ocular Surface Adverse Effects in Patients Receiving Topical Antiglaucoma Treatment

  2025cites this paper
• Short-term effects of antiglaucomatous topical medication on the ocular surface in Wistar rats

  2025cites this paper
• Quality by design steered approach for co-encapsulation of timolol maleate and dorzolamide hydrochloride in injectable liposomes.

  2024cites this paper
• Hot-melt extruded in situ gelling systems (MeltDrops Technology): Formulation development, in silico modelling and in vivo studies.

  2023cites this paper
• Comparing the Effectiveness and Adherence between Fixed and Non-Fixed Dorzolamide/Timolol Maleate in Open-Angle Glaucoma Patients in Hospital Universiti Sains Malaysia

  2023cites this paper
• The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability

  2021cites this paper
• Efficacy and safety of timolol-dorzolamide fixed-combination three times a day versus two times a day in newly diagnosed open-angle glaucoma

  2021cites this paper
• Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future

  2020cites this paper
• Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement

  2019cites this paper
• Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension.

  2019cites this paper
• Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013–2019)

  2019cites this paper
• [The role of fixed dose combinations in the treatment of primary open-angle glaucoma].

  2018cites this paper
• Update on the Medical Treatment of Primary Open-Angle Glaucoma

  2016cites this paper
• FIXED COMBINATIONS A mainstay of glaucoma management today and tomorrow

  2016cites this paper
• Hypokalemia and suspected renal tubular acidosis associated with topical carbonic anhydrase inhibitor therapy in a cat.

  2016cites this paper
• Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension.

  2016cites this paper
• A review of the pharmacology of carbonic anhydrase inhibitors for the treatment of glaucoma in dogs and cats.

  2015cites this paper
• Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog

  2015cites this paper
• Dual drug delivery from vitamin E loaded contact lenses for glaucoma therapy.

  2015cites this paper
• Intraocular Pressure–lowering Efficacy of Dorzolamide/Timolol Fixed Combination in Normal-tension Glaucoma

  2014cites this paper
• Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus

  2014cites this paper
• Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus

  2014cites this paper
• Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice

  2014cites this paper
• TİMOLOL/BRİNZOLOMİD KOMBİNASYONU İLE TİMOLOL/DORZOLOMİD KOMBİNASYONUN GÖZ TANSİYONU AÇISINDAN KARŞILAŞTIRILMASI

  2014cites this paper
• Intraocular Pressure-Reducing Effects After Treatment is Changed to Cosopt^|^reg; Monotherapy in Broadly Defined Primary Open-Angle Glaucoma or Ocular Hypertension

  2013cites this paper
• Stellenwert der Kombinationstherapie in der medikamentösen Glaukombehandlung

  2013cites this paper
• Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial

  2012cites this paper
• Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day

  2012cites this paper
• Cell viability score as an integrated indicator for cytotoxicity of benzalkonium chloride-containing antiglaucoma eyedrops.

  2012cites this paper
• Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs

  2012cites this paper
• Comparative study of in vitro ocular surface cytotoxicity of a fixed combination of 0.5% timolol/1% dorzolamide eyedrop and its components with 0.005% benzalkonium chloride.

  2012cites this paper
• Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma

  2011cites this paper
• Role of fixed combinations in the management of open-angle glaucoma

  2011cites this paper
• Additive intraocular pressure-lowering effect of dorzolamide 1 % / timolol 0 . 5 % fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma

  2011cites this paper
• From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch study

  2011cites this paper
• Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open‐angle glaucoma and ocular hypertension: 24‐month results of a randomized, double‐masked phase III study

  2010cites this paper
• Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension

  2010cites this paper
• Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension

  2010cites this paper
• Comparison of the effects of dorzolamide/timolol and latanoprost/timolol fixed combinations upon intraocular pressure and progression of visual field damage in primary open-angle glaucoma

  2010cites this paper
• Safety and Efficacy of Fixed Combination Travoprost-Timolol in the Lowering of Intraocular Pressure

  2010cites this paper
• Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol

  2010cites this paper
• Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial

  2010cites this paper
• Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma

  2010cites this paper
• Mean standard deviations for common glaucoma treatments

  2009cites this paper
• Considerations in glaucoma therapy: fixed combinations versus their component medications

  2009cites this paper
• Peut-on associer les associations xes médicamenteuses ? Is it possible to combine xed therapeutic associations ?

  2009cites this paper
• Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension

  2009cites this paper
• [Is it possible to combine fixed therapeutic associations?].

  2009cites this paper
• Managing Primary Open-angle Glaucoma – Ocular Tolerability, Compliance, Persistence and Patient Outcomes

  2009cites this paper
• Fixed-Combination Brimonidine/Timolol as Adjunctive Therapy to a Prostaglandin Analog: A 3-Month, Open-Label, Replacement Study in Glaucoma Patients

  2009cites this paper
• Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure

  2008cites this paper
• Pharmacological Management of Primary Open-Angle Glaucoma

  2008cites this paper
• The effects of dorzolamide 2% and dorzolamide/timolol fixed combination on retinal and optic nerve head blood flow in primary open-angle glaucoma patients

  2008cites this paper
• Predictive value of the efficacy of glaucoma medications in regulatory trials: Phase I–III to post-marketing studies

  2008cites this paper
• Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components

  2008cites this paper
• Rational use of the fixed combination of dorzolamide – timolol in the management of raised intraocular pressure and glaucoma

  2008cites this paper
• A One-Week Comfort Study of BID-Dosed Brinzolamide 1%/Timolol 0.5% Ophthalmic Suspension Fixed Combination Compared to BID-Dosed Dorzolamide 2%/Timolol 0.5% Ophthalmic Solution in Patients with Open-Angle Glaucoma or Ocular Hypertension

  2008cites this paper
• The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies.

  2008cites this paper
• Treatment of glaucoma patients with insufficient intraocular pressure control: a survey of German ophthalmologists in private practice.

  2008cites this paper
• Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic review

  2008cites this paper
• Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy

  2008cites this paper
• 24-hour control of intraocular pressure with 2% dorzolamide/0.5% timolol fixed-combination ophthalmic solution in open-angle glaucoma*

  2008cites this paper
• An Eight-week, Multicentric, Randomized, Interventional, Open-label, Phase 4, Parallel Comparison of the Efficacy and Tolerability of the Fixed Combination of Timolol Maleate 0.5%/Brimonidine Tartrate 0.2% Versus Fixed Combination of Timolol Maleate 0.5%/Dorzolamide 2% in Patients With Elevated Intr

  2008cites this paper
• Medical Management of Glaucoma

  2008cites this paper
• Treatment of glaucoma patients with insufficient intraocular pressure control: a survey of German ophthalmologists in private practice

  2008cites this paper
• Cardiovascular and Respiratory Considerations With Pharmacotherapy of Glaucoma and Ocular Hypertension

  2008cites this paper
• Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%

  2007cites this paper
• Use of Fixed-Dose Combination Drugs for the Treatment of Glaucoma

  2007cites this paper
• Ocular Comfort of Combination Glaucoma Therapies: Brimonidine 0.2%/Timolol 0.5% Compared with Dorzolamide 2%/Timolol 0.5%

  2007cites this paper
• Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension

  2007cites this paper
• Retrobulbar haemodynamic effects of the latanoprost/timolol and the dorzolamide/timolol fixed combinations in newly diagnosed glaucoma patients

  2007cites this paper
• Pharmacologic Management of Glaucoma in Childhood

  2007cites this paper
• Intraocular pressure lowering effect of dorzolamide/timolol fixed combination in patients with glaucoma who were unresponsive to prostaglandin analogs/prostamides*

  2007cites this paper
• Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta-analysis of randomized clinical trials.

  2007cites this paper
• Topical Dorzolamide 2%/Timolol 0.5% Ophthalmic Solution

  2006cites this paper
• Comparison of Intraocular Pressure Fluctuations Measured by Goldmann Applanation Tonometer and Pulsatile Ocular Blood Flow Analyser

  2006cites this paper
• Topical Drug Therapy in Glaucoma

  2006cites this paper
• Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.

  2006cites this paper
• Bimatoprost versus timolol and dorzolamide: Author reply

  2005cites this paper
• Modern alchemy: fixed combinations of glaucoma drugs.

  2005cites this paper
• Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.

  2005cites this paper
• Efficacy of the Dorzolamide/Timolol Fixed Combination Versus Latanoprost in the Treatment of Ocular Hypertension or Glaucoma: Combined Analysis of Pooled Data from Two Large Randomized Observer and Patient-Masked Studies

  2005cites this paper
• 12-Week Study Comparing the Fixed Combination of Brimonidine and Timolol with Concomitant Use of the Individual Components in Patients with Glaucoma and Ocular Hypertension

  2005cites this paper
• Timolol/dorzolamide combination therapy as initial treatment for intraocular pressure over 30 mm Hg.

  2005cites this paper
• The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.

  2005cites this paper
• A Three-Month, Multicenter, Double-Masked Study of the Safety and Efficacy of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Compared to Travoprost 0.004% Ophthalmic Solution and Timolol 0.5% Dosed Concomitantly in Subjects With Open Angle Glaucoma or Ocular Hypertension

  2005cites this paper
• Management of Glaucoma: Focus on Pharmacological Therapy

  2005cites this paper
• Reducing intraocular pressure: is surgery better than drugs?

  2004cites this paper
• Dorzolamide/Timolol Fixed Combination Versus Concomitant Administration of Brimonidine and Timolol in Patients with Elevated Intraocular Pressure: A 3-Month Comparison of Efficacy, Tolerability, and Patient-Reported Measures

  2004cites this paper
• Effects on Aqueous Flow of Dorzolamide Combined with Either Timolol or Acetazolamide

  2004cites this paper
• Comparing the fixed combination dorzolamide–timolol (Cosopt®) to concomitant administration of 2% dorzolamide (Trusopt®) and 0·5% timolol – a randomized controlled trial and a replacement study

  2004cites this paper
• Evolving Paradigms in the Medical Treatment of Glaucoma

  2004cites this paper
• Ocular hypotensive drugs.

  2004cites this paper
• Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials.

  2004cites this paper
• Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America.

  2004cites this paper
• Immediate postoperative use of a topical agent to prevent intraocular pressure elevation after pars plana vitrectomy with gas tamponade.

  2004cites this paper
• Fixed combinations of topical glaucoma medications

  2004cites this paper
• Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists’ offices

  2003cites this paper
• Experience with COSOPT, the fixed combination of timolol and dorzolamide, gained in Swiss ophthalmologists' offices.

  2003cites this paper
• A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.

  2003cites this paper